logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Metastatic Malignant Breast Neoplasm

    FiltersReset Filters
    4 results

    • herceptin

      (Trastuzumab)
      Genentech, Inc.
      Usage: Herceptin is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer in combination with paclitaxel, or as a single agent after previous regimens. It is also used with cisplatin and capecitabine for HER2-positive metastatic gastric cancer. Patient selection should utilize an FDA-approved diagnostic.

    • herceptin hylecta

      (Trastuzumab and hyaluronidase-oysk)
      Genentech, Inc.
      Usage: HERCEPTIN HYLECTA is indicated for adjuvant treatment of HER2 overexpressing breast cancer in adults, either as part of a combination regimen with specific chemotherapy agents or as a single agent after anthracycline-based therapy. It is also used for first-line and subsequent treatment of metastatic breast cancer.

    • herzuma

      (TRASTUZUMAB)
      Cephalon, Inc.
      Usage: HERZUMA is indicated for adults with HER2 overexpressing breast cancer, both in adjuvant and metastatic settings, and for metastatic gastric or gastroesophageal junction adenocarcinoma. Treatment modalities include combinations with specific chemotherapies or as a single agent, guided by FDA-approved diagnostics.

    • trazimera

      (trastuzumab-qyyp)
      Pfizer Laboratories Div Pfizer Inc
      Usage: TRAZIMERA is indicated for adjuvant treatment of HER2-overexpressing breast cancer (both node-positive and node-negative) and for metastatic breast cancer (in combination with paclitaxel or as a single agent). It is also indicated for HER2-overexpressing metastatic gastric cancer, used with cisplatin and capecitabine or 5-fluorouracil.